Achmea Investment Management B.V. Raises Stock Holdings in Cencora, Inc. (NYSE:COR)

Achmea Investment Management B.V. lifted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 8.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 125,870 shares of the company's stock after buying an additional 9,857 shares during the period. Achmea Investment Management B.V. owned about 0.07% of Cencora worth $28,281,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. JFS Wealth Advisors LLC raised its holdings in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in Cencora in the 4th quarter worth about $30,000. Kentucky Trust Co acquired a new position in Cencora in the 4th quarter worth about $33,000. Householder Group Estate & Retirement Specialist LLC increased its holdings in Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares in the last quarter. Finally, WASHINGTON TRUST Co increased its holdings in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of recent research reports. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday. Evercore ISI upped their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Mizuho assumed coverage on Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target for the company. Finally, Wells Fargo & Company increased their price target on Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and an average target price of $277.90.

Remove Ads

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the sale, the chief executive officer now directly owns 51,070 shares of the company's stock, valued at $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,648 shares of company stock worth $3,382,462. Corporate insiders own 10.80% of the company's stock.

Cencora Trading Up 0.6 %

Shares of Cencora stock traded up $1.64 on Thursday, hitting $255.64. 1,038,563 shares of the company's stock traded hands, compared to its average volume of 1,357,794. The company has a fifty day moving average of $247.01 and a two-hundred day moving average of $238.93. The company has a market capitalization of $49.57 billion, a price-to-earnings ratio of 36.36, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a one year low of $214.77 and a one year high of $263.70.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.86%. Cencora's payout ratio is currently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.